Clinical characteristics and prognosis of acute erythroleukemia in children.
10.7499/j.issn.1008-8830.2405138
- Author:
Ping ZHU
1
;
Wen-Jing QI
1
;
Ye-Qing TAO
1
;
Ding-Ding CUI
1
;
Guang-Yao SHENG
1
;
Chun-Mei WANG
1
Author Information
1. Department of Children's Hematology and Oncology, First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.
- Publication Type:Journal Article
- Keywords:
Acute erythroleukemia;
Child;
Clinical characteristic;
Prognosis
- MeSH:
Humans;
Male;
Female;
Prognosis;
Child, Preschool;
Retrospective Studies;
Child;
Leukemia, Erythroblastic, Acute/diagnosis*;
Infant;
Adolescent
- From:
Chinese Journal of Contemporary Pediatrics
2025;27(1):88-93
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVES:To investigate the clinical characteristics and prognosis of acute erythroleukemia (AEL) in children.
METHODS:A retrospective analysis was conducted on the clinical data, treatment, and prognosis of 8 children with AEL treated at the First Affiliated Hospital of Zhengzhou University from January 2013 to December 2023.
RESULTS:Among the 7 patients with complete bone marrow morphological analysis, 4 exhibited trilineage dysplasia, with a 100% incidence of erythroid dysplasia (7/7), a 71% incidence of myeloid dysplasia (5/7), and a 57% incidence of megakaryocytic dysplasia (4/7). Immunophenotyping revealed that myeloid antigens were primarily expressed as CD13, CD33, CD117, CD38, and CD123, with 4 cases expressing erythroid antigens CD71 and 2 cases expressing CD235a. Chromosomal analysis indicated that 2 cases presented with abnormal karyotypes, including +8 in one case and +4 accompanied by +6 in another; no complex karyotypes were observed. Genetic abnormalities were detected in 4 cases, with fusion genes including one case each of dup MLL positive and EVI1 positive, as well as mutations involving KRAS, NRAS, WT1, and UBTF. Seven patients received chemotherapy, with 6 achieving remission after one course of treatment; 2 underwent hematopoietic stem cell transplantation, and all had disease-free survival. Follow-up (median follow-up time of 6 months) showed that only 3 patients survived (2 cases after hematopoietic stem cell transplantation and 1 case during treatment).
CONCLUSIONS:Children with AEL have unique clinical and biological characteristics, exhibit poor treatment response, and have a poor prognosis; however, hematopoietic stem cell transplantation may improve overall survival rates.
